4 Given these findings, as indicated in the National Comprehensive Cancer Network (NCCN) guidelines, octreotide scans are not recommended for surveillance after resection, as an adjunct for tumor staging, or for monitoring the status of advanced disease.
Although our report was controversial, a subsequent investigation evaluated the clinical utility of octreotide scans in the diagnosis and management of NET patients and also concluded that it did not alter surgical management. We advocated for the use of octreotide scans to test for the presence of the somatostatin receptor (SSTR) but not to follow the extent of disease. Based on our findings, we concluded that advances made in cross-sectional imaging changed the relative utility of octreotide scans. Octreotide scans, however, identified more asymptomatic and unsuspected bone metastases.
#NETSPOT NUCLEAR MEDICINE 3 VIALS SERIES#
3 In our institutional series of 121 patients, cross-sectional imaging detected more NET soft tissue lesions than octreotide scans. In 2011, our group evaluated the clinical utility of octreotide scans in detecting additional NET lesions as compared to conventional cross-sectional imaging. 1 While octreotide scans have the advantage of whole-body visualization, they also have limitations, including low spatial resolution, uptake of the radiotracer in normal organs, and increased burden on patients requiring multiple visits and scans over 2–3 days. In 1994, the octreotide scan (somatostatin receptor scintigraphy with 111In-pentetreotide) was approved for imaging of neuroendocrine tumors (NETs) based on studies suggesting that octreotide scans were better at localizing and staging NETs when compared to conventional cross-sectional imaging (computed tomography (CT) and/or magnetic resonance imaging (MRI)).
0 kommentar(er)
